5-biphenyl-4-yl-6-chloro-2-(methylsulfonyl)-1H-benzimidazole | 1219741-56-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-biphenyl-4-yl-6-chloro-2-(methylsulfonyl)-1H-benzimidazole
• 英文别名: 6-chloro-2-methylsulfonyl-5-(4-phenylphenyl)-1H-benzimidazole
• CAS: 1219741-56-6
• 化学式: C₂₀H₁₅ClN₂O₂S
• 分子量: 382.87
• InChiKey: IPLCUKZPSNUHCF-UHFFFAOYSA-N

物化性质

• 沸点：
  631.3±47.0 °C(Predicted)
• 密度：
  1.370±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  71.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-biphenyl-4-yl-6-chloro-2-(methylsulfonyl)-1H-benzimidazole 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 生成 ethyl 3-{[5-(biphenyl-4-yl)-6-chloro-1-{[2-(trimethylsilyl)ethoxy]-methyl}-1H-benzimidazol-2-yl]oxy}cyclobutanecarboxylate
  参考文献：
  名称：

  [EN] NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS
  [FR] NOUVEAUX DÉRIVÉS BENZIMIDAZOLE CYCLIQUES UTILES COMME AGENTS ANTIDIABÉTIQUES

  摘要：

  结构式（I）的新化合物是AMP-蛋白激酶的激活剂，并且在治疗、预防和抑制由AMPK激活的蛋白激酶介导的疾病中具有用途。本发明的化合物在治疗2型糖尿病、高血糖、代谢综合征、肥胖、高胆固醇血症和高血压方面具有用途。

  公开号：

  WO2011106273A1
• 作为产物：
  描述：

  2-硝基-5-氯苯胺 在 四(三苯基膦)钯 potassium phosphate 、 N-碘代丁二酰亚胺 、 铁粉 、 potassium carbonate 、 氯化铵 、 溶剂黄146 、 间氯过氧苯甲酸 、 potassium hydroxide 作用下， 以 1,4-二氧六环 、 乙醇 、 二氯甲烷 、 水 、 丙酮 为溶剂， 反应 8.17h， 生成 5-biphenyl-4-yl-6-chloro-2-(methylsulfonyl)-1H-benzimidazole
  参考文献：
  名称：

  [EN] NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS
  [FR] NOUVEAUX DÉRIVÉS BENZIMIDAZOLE CYCLIQUES UTILES COMME AGENTS ANTIDIABÉTIQUES

  摘要：

  结构式（I）的新化合物是AMP-蛋白激酶的激活剂，并且在治疗、预防和抑制由AMPK激活的蛋白激酶介导的疾病中具有用途。本发明的化合物在治疗2型糖尿病、高血糖、代谢综合征、肥胖、高胆固醇血症和高血压方面具有用途。

  公开号：

  WO2011106273A1

文献信息

• NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS
  申请人：BOOKSER BRETT C.

  公开号：US20100081643A1

  公开（公告）日：2010-04-01

  Novel compounds of the structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.

  结构式（I）的新化合物是AMP-蛋白激酶的激活剂，并且在治疗、预防和抑制由AMPK激活的蛋白激酶介导的疾病方面非常有用。本发明的化合物在治疗2型糖尿病、高血糖、代谢综合征、肥胖、高胆固醇血症和高血压方面非常有用。
• NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS
  申请人：Jiang Jinlong

  公开号：US20120309736A1

  公开（公告）日：2012-12-06

  Novel compounds of the structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.

  结构式（I）的新型化合物是AMP蛋白激酶的激活剂，并可用于治疗、预防和抑制由AMPK激活的蛋白激酶介导的疾病。本发明的化合物可用于治疗2型糖尿病、高血糖、代谢综合征、肥胖症、高胆固醇血症和高血压。
• Cyclic benzimidazole derivatives useful as anti-diabetic agents
  申请人：Bookser Brett C.

  公开号：US08394969B2

  公开（公告）日：2013-03-12

  Novel compounds of the structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.

  结构式（I）的新型化合物是AMP-蛋白激酶的激活剂，可用于治疗、预防和抑制由AMPK激活的蛋白激酶介导的疾病。本发明的化合物可用于治疗2型糖尿病、高血糖、代谢综合征、肥胖症、高胆固醇血症和高血压。
• Hit-to-Lead Optimization and Discovery of 5-((5-([1,1′-Biphenyl]-4-yl)-6-chloro-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)oxy)-2-methylbenzoic Acid (MK-3903): A Novel Class of Benzimidazole-Based Activators of AMP-Activated Protein Kinase
  作者：Ping Lan、F. Anthony Romero、Dariusz Wodka、Andrew J. Kassick、Qun Dang、Tony Gibson、Daniel Cashion、Gaochao Zhou、Yuli Chen、Xiaoping Zhang、Aihua Zhang、Ying Li、Maria E. Trujillo、Qing Shao、Margaret Wu、Shiyao Xu、Huaibing He、Deidre MacKenna、Jocelyn Staunton、Kevin T. Chapman、Ann Weber、Iyassu K. Sebhat、Gergely M. Makara

  DOI：10.1021/acs.jmedchem.7b01344

  日期：2017.11.9

  AMP-activated protein kinase (AMPK) plays an essential role as a cellular energy sensor and master regulator of metabolism in eukaryotes. Dysregulated lipid and carbohydrate metabolism resulting from insulin resistance leads to hyperglycemia, the hallmark of type 2 diabetes mellitus (T2DM). While pharmacological activation of AMPK is anticipated to improve these parameters, the discovery of selective, direct activators has proven challenging. We now describe a hit-to-lead effort resulting in the discovery of a potent and selective class of benzimidazole-based direct AMPK activators, exemplified by 5-((5-([1,1'-biphenyl]-4-yl)-6-chloro-1H-benzo[d]imidazol-2-yl)oxy)-2-methylbenzoic acid, 42 (MK-3903). Compound 42 exhibited robust target engagement in mouse liver following oral dosing, leading to improved lipid metabolism and insulin sensitization in mice.
• Discovery of MK-8722: A Systemic, Direct Pan-Activator of AMP-Activated Protein Kinase
  作者：Danqing Feng、Tesfaye Biftu、F. Anthony Romero、Ahmet Kekec、James Dropinski、Andrew Kassick、Shiyao Xu、Marc M. Kurtz、Anantha Gollapudi、Qing Shao、Xiaodong Yang、Ku Lu、Gaochao Zhou、Daniel Kemp、Robert W. Myers、Hong-Ping Guan、Maria E. Trujillo、Cai Li、Ann Weber、Iyassu K. Sebhat

  DOI：10.1021/acsmedchemlett.7b00417

  日期：2018.1.11

  5'-Adenosine monophosphate-activated protein kinase (AMPK) is a key regulator of mammalian energy homeostasis and has been implicated in mediating many of the beneficial effects of exercise and weight loss including lipid and glucose trafficking. As such, the enzyme has long been of interest as a target for the treatment of Type 2 Diabetes Mellitus. We describe the optimization of beta 1-selective, liver-targeted AMPK activators and their evolution into systemic pan-activators capable of acutely lowering glucose in mouse models. Identifying surrogates for the key acid moiety in early generation compounds proved essential in improving beta 2-activation and in balancing improvements in plasma unbound fraction while avoiding liver sequestration.